Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis

Abstract Background and Aims It has been described that recompensation can improve prognosis in patients with cirrhosis. However, recompensation after transjugular intrahepatic portosystemic shunt (TIPS) has not been studied. We evaluated the impact of recompensation after TIPS on the risk of hepatocellular carcinoma (HCC) and death, and we compared it with compensated cirrhosis patients. Methods An observational study of consecutive patients with cirrhosis undergoing TIPS between 2008 and 2022 was performed. Baveno VII definition of recompensation was used including patients with or without diuretics/Hepatic encephalopathy prophylaxis. A prospective cohort of consecutive compensated cirrhosis patients was used for comparison. Results Overall, 208 patients with cirrhosis were included, 92 compensated and 116 decompensated who underwent TIPS. After 1 year, 24% achieved recompensation. Liver function (MELD 12 ± 5 vs. 15 ± 6; p = .049), LDL‐cholesterol (97 mg/dL vs. 76 mg/dL, p = .018), white cell count (7.96 × 10 9 /dL vs. 6.24 × 10 9 /dL, p = .039) and platelets (129 × 10 9 /dL vs. 101 × 10 9 /dL, p = .039) were associated with recompensation. Recompensation was associated with a reduction in the risk of HCC ( p = .020). Multivariable analysis showed that this risk was significantly higher in non‐recompensated patients ( p = .003) but no differences were observed in recompensated compared with compensated patients ( p = .816). Similarly, decompensated patients presented lower survival rates ( p = .011), while no differences were observed between recompensated and compensated patients ( p = .677). Conclusions Recompensation after TIPS has a clear impact on the incidence of HCC and death, with a similar prognosis than patients with compensated cirrhosis. Liver function is associated with recompensation, suggesting the importance of considering early TIPS in patients with indication.